Neurocrine Biosciences Inc (NBIX)

Add to Watchlists
Create an Alert
79.03 -0.97  -1.21% NASDAQ May 17, 20:00 Delayed 2m USD
View Full Chart
NBIX Price Chart
View All Key Stats

NBIX Key Stats

View All NBIX News

NBIX News

View All Events

NBIX Events

Date Type Description
07/31/2019 16:30 EDT Misc Neurocrine Biosciences Inc Second Quarter Earnings Conference Call in 2019
07/31/2019 Earnings Neurocrine Biosciences Inc Second Quarter Earnings in 2019 Release
04/29/2019 16:30 EDT Misc Neurocrine Biosciences Inc First Quarter Earnings Conference Call in 2019
04/29/2019 Earnings Neurocrine Biosciences Inc First Quarter Earnings in 2019 Release
02/05/2019 16:30 EST Misc Neurocrine Biosciences Inc Fourth Quarter Earnings Conference Call in 2018
02/05/2019 Earnings Neurocrine Biosciences Inc Fourth Quarter Earnings in 2018 Release
11/05/2018 16:30 EST Misc Neurocrine Biosciences Inc Third Quarter Earnings Conference Call in 2018
11/05/2018 Earnings Neurocrine Biosciences Inc Third Quarter Earnings in 2018 Release
07/31/2018 16:30 EDT Misc Neurocrine Biosciences Inc Second Quarter Earnings Conference Call in 2018
07/31/2018 Earnings Neurocrine Biosciences Inc Second Quarter Earnings Results in 2018
View All Performance Charts

NBIX Total Returns Comparison

NBIX Fundamentals

Income Statement View Statement

Revenue (TTM) 518.56M
Total Expenses (TTM) 545.21M
Net Income (TTM) -39.19M

Balance Sheet View Statement

Total Assets (Quarterly) 957.72M
Total Liabilities (Quarterly) 548.45M
Shareholders Equity (Quarterly) 409.28M

Cash Flow Statement View Statement

Cash from Operations (TTM) 27.36M
Cash from Investing (TTM) -144.89M
Cash from Financing (TTM) 15.98M

NBIX Ratings

Advertisement

NBIX One Page Reports

NBIX Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 79.03
Price Target Upgrade
Price Target Upside (Daily) Upgrade
Edit

Profile

  • URL: http://www.neurocrine.com
  • Investor Relations URL: http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-news&nyo=0
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Jul. 31, 2019
  • Last Earnings Release: Apr. 29, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Dec. 29, 1995
  • Description: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

NBIX Comparables

Edit
VYGR Voyager Therapeutics Inc
MBIO Mustang Bio Inc
ZBH Zimmer Biomet Holdings Inc
SAGE Sage Therapeutics Inc
RGEN Repligen Corp

Excel Add-In Codes

  • Name: =YCI("NBIX","name")
  • Description: =YCI("NBIX","description")
  • Sector: =YCI("NBIX","sector")
  • Industry: =YCI("NBIX","industry")
  • Est. Current Fiscal Year End: =YCI("NBIX","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Other NBIX Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.